Danaher Corporation (DHR)
Danaher Corporation (DHR) Q4 2025 Earnings Call Transcript
Danaher Corporation (DHR) Q4 2025 Earnings Call Transcript
Compared to Estimates, Danaher (DHR) Q4 Earnings: A Look at Key Metrics
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher (DHR) Beats Q4 Earnings and Revenue Estimates
Danaher (DHR) came out with quarterly earnings of $2.23 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.14 per share a year ago.
Danaher forecasts 2026 profit in line with estimates on pharma spending recovery
Life sciences firm Danaher Corp forecast annual profit largely in line with Wall Street estimates on Wednesday and beat fourth-quarter profit and revenue expectations, as improving conditions in the pharmaceutical market and reduced policy uncertainties offset weakness in academic research funding.
Insights Into Danaher (DHR) Q4: Wall Street Projections for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Danaher (DHR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Danaher Gears Up to Post Q4 Earnings: What Lies Ahead for the Stock?
DHR is set to report Q4 results on Jan. 28, with revenues seen up 3.9% and bioprocessing and diagnostics strength in focus.
Danaher (DHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Danaher Corporation (DHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Danaher Corporation (DHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Danaher: Biotech Strength And Cash Generation Reinforce A $250 Fair Value
Danaher Corporation is rated Buy with a target price of $250, implying 10.5% upside from $226.25. DHR's strong Q3 execution featured 4.5% revenue growth, margin expansion to 37.2%, and robust free cash flow conversion at 145%. Biotechnology drives growth while Life Sciences stagnates; management guides for modest FY25 growth and margin expansion in 2026.
Danaher (DHR) Up 2% Since Last Earnings Report: Can It Continue?
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
Danaher Corporation (DHR) Presents at Jefferies London Healthcare Conference 2025 Transcript
Danaher Corporation ( DHR ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants Rainer Blair - President, CEO & Director Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division I think we'll kick it off. Welcome, everybody.
The Richest 0.1% Are Buying These 3 Dividend Stocks Right Now
When ultra-rich investors start coalescing into the same names or put an unusually large amount of money into a single stock, that should raise more interest.
